XSHE
300957
Market cap2.05bUSD
Oct 09, Last price
33.14CNY
1D
1.66%
1Q
4.54%
IPO
-81.17%
Name
Yunnan Botanee Bio-Technology Group Co Ltd
Chart & performance
P/E
27.61
P/S
2.61
EPS
1.20
Div yield, %
1.84%
Shrs. gr., 5y
-0.10%
Rev. gr., 5y
15.24%
Revenues
5.36b
-6.58%
Net income
506m
+0.53%
CFO
977m
+40.54%
Dividend
Sep 22, 20260.15 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yunnan Botanee Bio-Technology Group Co.LTD operates within the Chinese market, specializing in the development and distribution of a broad spectrum of skincare formulations. Its comprehensive product line encompasses cleansing and makeup removal solutions, facial masks, toners, serums, hydrating moisturizers, eye creams, refreshing facial sprays, sun protection items, cosmetic foundations, and general body care products. This enterprise, founded in 2010, is strategically headquartered in Kunming, China.
Key people
Zhenyu Guo
Chairman of the Board, General Manager · since 2019
Shenghui Bian
Deputy General Manager · since 2024
Shaoyang Gao
Senior Deputy General Manager, Director · since 2024
Xiao Ma
Senior Deputy General Manager, Director · since 2024
Long Wang
Chief Financial Officer, Deputy General Manager, Company Secretary · since 2023
Feifei Wang
Deputy General Manager · since 2023
Xiaojing Wu
Deputy General Manager · since 2025
Kevin Guo
Director · since 2025
Mei Zhang
General Manager, Director · since 2023
Wei Zhou
Director · since 2019
Ning Li
Independent Director · since 2019
Hule Liu
Independent Director · since 2025
Ao Wang
Independent Director · since 2019
Ronghui Yao
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||